Badanie nad anakinrą u dzieci z młodzieńczym idiopatycznym zapaleniem stawów (systemowym)

Systemic Juvenile Idiopathic Arthritis (sJIA), also known as Still's disease, is an autoimmune disorder that affects the joints and can cause inflammation throughout the body. This study focuses on a treatment strategy using anakinra, a medication that helps reduce inflammation by blocking a specific protein in the body. Anakinra is given as an injection under the skin and is used to help manage symptoms in children and adolescents with sJIA.

The purpose of the study is to explore a new approach to using anakinra, guided by a specific marker in the blood called IL-18, to determine the best time to reduce or stop the medication. The study aims to see if this method can help maintain the disease in an inactive state with fewer injections compared to traditional methods. Participants will receive anakinra and be monitored to see how their condition responds over time.

Throughout the study, the number of injections needed to keep the disease inactive will be recorded, along with any changes in the disease's activity. The study will also track how many participants can stop the medication while keeping the disease under control, as well as any side effects or need for changes in treatment. This research hopes to improve the management of sJIA by finding a more efficient way to use anakinra, potentially reducing the burden of treatment for patients. A placebo may be used in some parts of the study to compare results.